



Gender-Specific and U-Shaped Relationship Between Serum Uric Acid and All-Cause Mortality Among Chinese Older Adults: A National Population-Based Longitudinal Study

Yinqiao Dong^{1,2,3†}, Zhiqiang Wang^{1†}, Suping Wang^{1†}, Ruijie Chang¹, Yujie Liu¹, Rongxi Wang¹, Hui Chen¹, Shangbin Liu¹, Changlin Qian^{4*}, Yong Cai^{2,3*} and Fan Hu^{2,3*}

¹School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China, ²Hongqiao International Institute of Medicine, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, ³Center for Community Healthcare, Hospital Development Institute Shanghai Jiao Tong University, Shanghai, China, ⁴Department of General Surgery, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China,

OPEN ACCESS

[]PF

Edited by:

Gabriel Gulis, University of Southern Denmark, Denmark

Reviewed by:

Pai Feng Hsu, Taipei Veterans General Hospital, Taiwan

*Correspondence:

Changlin Qian qianchanglin@renji.com Yong Cai caiyong202028@hotmail.com Fan Hu joyking2003@163.com

This Original Article is part of the IJPH Special Issue "Public Health and Primary Care, is 1+1=1?"

⁺These authors have contributed equally to this work and share first authorship

> Received: 28 February 2023 Accepted: 19 April 2023 Published: 03 May 2023

Citation:

Dong Y, Wang Z, Wang S, Chang R, Liu Y, Wang R, Chen H, Liu S, Qian C, Cai Y and Hu F (2023) Gender-Specific and U-Shaped Relationship Between Serum Uric Acid and All-Cause Mortality Among Chinese Older Adults: A National Population-Based Longitudinal Study. Int J Public Health 68:1605934. doi: 10.3389/ijph.2023.1605934 **Objectives:** This study aimed to prospectively investigate gender-specific relationship between hyperuricemia and all-cause mortality among Chinese older adults.

Methods: The study was based on the Chinese Longitudinal Healthy Longevity Survey (CLHLS) 2008–2018, a prospective nationwide cohort of older adults in China. Multivariate Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% Cls for all-cause mortality. Restricted cubic splines (RCS) were conducted to explore the dose-response relationship between SUA levels and all-cause mortality.

Results: For older women, compared to the participants in the third quartile of SUA level, those in the highest quartile of SUA was associated with significantly higher risk of all-cause mortality in the fully adjusted model (HR: 1.41, 95% CI: 1.03–1.92). No significant associations between SUA levels and all-cause mortality were observed in older men. The present study further found a U-shaped non-linear relationship between SUA levels and all-cause mortality in both sexes of older population (P for non-linear <0.05).

Conclusions: This study provided prospective epidemiological evidence for the predictive role of SUA on all-cause mortality among the Chinese aging population over 10 years of follow-up, while revealing considerable gender-related differences.

Keywords: mortality, older adults, cohort study, serum uric acid, gender difference

INTRODUCTION

Serum uric acid (SUA), the final enzymatic product of purine metabolism, is a biological marker for the diagnosis of hyperuricemia. Increasing evidence linked hyperuricemia to a variety of adverse health outcomes, including hypertension (1, 2), obesity and diabetes (3, 4), dyslipidemia (5, 6), and kidney disease (7, 8), which all contributed to changes in all-cause mortality (9–11). However, epidemiological evidence on the relationship between hyperuricemia and all-cause mortality in older people remains inadequate and controversial. Several studies demonstrated that hyperuricemia was

positively associated with all-cause mortality in the elder population (12–14). In contrast, few studies revealed that inverse associations between SUA levels and all-cause mortality resulting from SUA as a powerful antioxidant that has a protective effect on diseases (15). In addition, most of these studies were observational research that contained inevitable possible biases, thus whether hyperuricemia is an independent and causal risk factor for increased all-cause mortality, especially in Chinese older people remains unknown.

Higher SUA levels in men than in women at all ages have been widely demonstrated (16). Most previous studies on SUA levels and all-cause mortality only adjusted for sex in the models and seldom conducted sex-specific association analyses. Considering the gender differences in the distribution of SUA levels, some studies have analyzed the relationship between SUA levels and all-cause mortality, but the epidemiological evidence for the relationship in older adults is limited and inconsistent. On the one hand, several meta-analyses and observational studies have found that gender differences may modify the relationship between hyperuricemia and all-cause mortality, for example, only in males (17), females (18, 19) and/or both (12, 20). On the other hand, several meta-analyses and observational studies have shown no statistically significant gender differences in the association between SUA levels and all-cause mortality risk (21, 22). Most of the above contradictory results are based on observational studies and lack of evidence from prospective studies.

Considering those mentioned above, the aim of the present study was to examine the prospective associations between hyperuricemia and all-cause mortality in Chinese older adults over 10 years of follow-up. To our knowledge, few studies have examined the modified effect of gender on the longitudinal association between hyperuricemia and all-cause mortality among Chinese older adults. Therefore, this study further examined the gender differences in the relationship between hyperuricemia and all-cause mortality in the Chinese aging population.

METHODS

Study Design and Participants

The CLHLS is the first and largest nationwide, community-based, longitudinal prospective cohort survey in China. The CLHLS were performed by randomly selected from counties or cities in 23 provinces across China, covering about 85% percent of the Chinese population (23). The CLHLS survey was initiated in 1998, and follow-up survey were conducted in 2000, 2002, 2005, 2008/2009, 2011/2012, 2014, and 2017/2018 (24). The CLHLS contained many types of information, including demographics, lifestyle, health status, and daily activities of older people, including a large percentage of the oldest population. Since biological indicator data were only available in the 2008–2009, 2011–2012, and 2014 waves, we therefore selected participants enrolled in 2008–2009 wave as our baseline population for followup. In 2009, a biomarker substudy was conducted in seven longevity regions, including Sanshui of Guangdong Province, Yongfu of Guangxi Autonomous Area, Chengmai of Hainan Province, Xiayi of Henan Province, Zhongxiang of Hubei Province, Mayang of Hunan Province, and Laizhou of Shandong Province. The CLHLS study was approved by the Research Ethics Committee of Peking University (IRB00001052-13074). Written informed consent was provided from all participants.

Initially, A total of 2035 participating older adults provided blood sample data in the 5th wave (2008-2009) of CLHLS. According to the following exclusion criteria, we retained 1,067 Chinese older adults in this study after applying the following exclusion criteria. 1) We excluded participants who had no participant ID and who were younger than 60 years old. 2) We excluded people with missing SUA and other biochemical data. 3) We excluded participants who were unable to match the 2008-2018 follow-up longitudinal survey. 4) We excluded participants due to their unknown information. The flow chart of the study population was shown in **Supplementary Figure S1**. The study population was divided into four groups according to quartiles of SUA levels by gender. The cutoff points were <241.30, 241.30-303.90, 303.90-355.80 and ≥355.80 µmol/L for males, and <201.65, 201.65-245.75, 245.75-301.70, and \geq 301.70 µmol/L for females.

Biochemical Measurements

Fasting venous blood samples were collected by trained medical personnel from all willing participant who had fasted overnight. These samples were collected into 5 mL heparin anticoagulant vacuum tubes and centrifuged at 20°C and 3000 × g for 10 min. The plasma was isolated and frozen at -20° C, shipped through cold-chained to the central laboratory at Capital Medical University in Beijing, and stored at -80° C until biochemical analysis. Plasma concentrations of blood urea nitrogen (BUN), creatinine, serum uric acid (SUA), fasting blood glucose, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and triglyceride (TG) were measured using an automatic biochemistry analyzer (Hitachi 7180, Swiss Roche Company, Tokyo, Japan).

Study Outcome During Prospective Follow-Up

The outcome of our study was all-cause mortality from 1 January 2008 to 31 December 2018. Mortality status was obtained from a publicly available dataset of the CLHLS, which captured the vital status of survey participants from baseline to 31 December 2018. If a participant missed the follow-up visit, the survival time was defined as the interval between baseline and time of missed visits. Survival time was calculated from the survey date at baseline until the date of death, or the interview date of follow-up survey, or lost visit date, whichever came first.

Covariates

Covariates were collected information using a standardized questionnaire administered by the trained interviewers during an household interview. The present study adjusted for sociodemographic variables, health characteristics, and TABLE 1 | Baseline characteristics of all study participants according to serum uric acid quartiles (Chinese Longitudinal Health Longevity Survey, China, 2008–2018).

$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$	Characteristics	All subjects		Serum uric acid	l quartiles (µmol/L)		<i>p</i> -value
		(N = 1,067)	Q1 (N = 266)	Q2 (N = 268)	Q3 (N = 266)	Q4 (N = 267)	
	Demographic characteristics						
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Age (years)	84.84 ± 13.15	81.23 ± 13.09	84.53 ± 13.59	86.00 ± 12.68	87.57 ± 12.45	<0.001 ^{e, f}
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Female	608 (57 0)	152 (57 1)	152 (56 7)	151 (56.8)	153 (57 0)	0.999
	Category of residence	000 (0110)			101 (0010)	100 (0110)	<0.001
	City/Town	245 (23.0)	40 (15 0)	54 (20 1)	66 (24 8)	85 (31.8)	
Encompositio Income (FMB/year) Enc. (p.1.4) Enc. (p.1.4) <thenc.(p.1.4)< th=""> Enc. (p.1.4) <</thenc.(p.1.4)<>	Bural	822 (77 0)	226 (85.0)	214 (79.9)	200 (75.2)	182 (68 2)	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Economic income (PMB/year)	022 (11.0)	220 (00.0)	214 (10.0)	200 (10.2)	102 (00.2)	-0.001
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$		500 (47 7)	161 (60 5)	105 (46 6)	115 (42 0)	108 (40.4)	<0.001
$ \begin{array}{c c c c c c c } 210,000 & 356 [82.5] & 163 [85.5] & 163 [85.4] & 151 [86.6] & 151 [86.6] & 151 [86.6] & 151 [86.6] & 151 [86.6] & 151 [86.6] & 151 [86.6] & 152 [86.4] & 158 [70.4] & $	< 10,000	509 (47.7)	101 (00.5)	123 (40.0)	115 (45.2)	100 (40.4)	
	≥10,000	558 (52.3)	105 (39.5)	143 (53.4)	151 (56.8)	159 (59.6)	
Since 0.080 748 (70.1) 168 (69.9) 192 (71.6) 182 (68.4) 188 (70.4) 188 (70.4) Yes 319 (29.9) 300 (00.1) 76 (22.4) 84 (31.6) 79 (23.6) 79 (23.6) Drink 60.00 79 (74.7) 195 (73.3) 215 (80.2) 202 (75.9) 185 (60.3) 202 (75.9) 185 (60.3) 200 (75.9) 400 (75.9)	Lifestyle						
No 748 (70.1) 186 (69.9) 192 (71.6) 182 (68.4) 188 (70.4) Yes 319 (29.9) 80 (80.1) 76 (28.4) 84 (31.6) 79 (79.6) 30 (30.9) No 797 (74.7) 195 (73.3) 215 (80.2) 202 (75.9) 185 (69.3) (0.001) Yes 270 (25.3) 71 (25.7) 53 (19.8) 64 (24.1) 82 (30.7) (0.001) Current/Former 280 (26.2) 45 (16.9) 69 (25.7) 79 (29.7) 87 (32.6) (0.01) Other 787 (73.8) 221 (83.1) 199 (74.3) 187 (70.3) 180 (67.4) 120 (67.4)	Smoke						0.880
Yes319 (29)319 (29)30 (30.1)76 (28.4)48 (31.6)79 (28.6)79 (28.7)No797 (47.7)195 (73.3)216 (60.2)202 (75.9)185 (69.3)71Prysical activity70 (25.3)71 (26.7)53 (19.8)64 (24.1)82 (30.7)Current/Former280 (26.2)45 (16.9)60 (25.7)79 (29.7)87 (32.6)Nore797 (73.8)221 (83.1)199 (74.3)187 (70.3)180 (67.4)DetaryFresh fuit79 (25.5)77 (28.9)98 (36.6)94 (35.3)110 (41.2)Sometines/Rarky or never688 (64.5)189 (71.1)170 (63.4)172 (64.7)157 (58.8)Sometines/Rarky or never93 (6.7)22 (8.3)30 (11.2)18 (68.)23 (8.6)Awaya/Otten97 (41.3)24 (41.7)238 (88.8)24 (61.7)143 (53.6)Awaya/Otten93 (6.7)184 (69.2)157 (58.6)164 (61.7)143 (53.6)Awaya/Otten419 (53.3)28 (0.6)114 (41.4)122 (38.3)124 (46.1)Awaya/Otten112 (10.5)28 (10.5)28 (10.4)33 (12.4)23 (8.6)Eat mait0.00223 (87.6)144 (61.7)44 (61.7)Awaya/Otten152 (10.5)28 (10.6)133 (12.4)23 (8.6)Sometines/Rarky or never39 (37.4)133 (60.0)166 (61.9)181 (60.0)188 (70.4)Sometines/Rarky or never39 (35.6)123 (60.0)166 (61.9)181 (60.0)186 (70.4)Sometines/Rarky or never39 (35.6	No	748 (70.1)	186 (69.9)	192 (71.6)	182 (68.4)	188 (70.4)	
$ \begin{array}{ c c c } \hline \text{Driv} & & & & & & & & & & & & & & & & & & &$	Yes	319 (29.9)	80 (30.1)	76 (28.4)	84 (31.6)	79 (29.6)	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Drink						0.030
Yes270 (25.3)71 (26.7)53 (19.8)64 (24.1)82 (30.7)Physical activity $ -$ <td>No</td> <td>797 (74.7)</td> <td>195 (73.3)</td> <td>215 (80.2)</td> <td>202 (75.9)</td> <td>185 (69.3)</td> <td></td>	No	797 (74.7)	195 (73.3)	215 (80.2)	202 (75.9)	185 (69.3)	
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	Yes	270 (25.3)	71 (26.7)	53 (19.8)	64 (24.1)	82 (30.7)	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Physical activity	× ,	× ,			× ,	<0.001
$\begin{array}{ c c c c c c c } \hline \begin{tabular}{ c c c c c c c } \hline begin{tabular}{ c c c c c c c c c c c c c c c c c c c$	Current/Former	280 (26 2)	45 (16.9)	69 (25 7)	79 (29 7)	87 (32 6)	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	None	787 (73.8)	221 (83.1)	199 (74 3)	187 (70.3)	180 (67.4)	
$\begin{array}{ c c c c c } \mbox{Leasy} \\ \hline Fresh fult \\ \hline Always/Often & 379 (35.5) & 77 (28.9) & 98 (36.6) & 94 (35.3) & 110 (41.2) \\ \hline Always/Often & 688 (64.5) & 189 (71.1) & 170 (63.4) & 172 (64.7) & 157 (58.6) \\ \hline Fresh vegetables & & & & & & & & & & & & & & & & & & &$	Dioton	101 (10.0)	221 (00.1)	100 (14.0)	167 (70.6)	100 (01.4)	
$\begin{array}{ c c c c c } \hline \mbox{Tright frame} & $77 (28.9) & 98 (86.6) & 94 (35.3) & 110 (41.2) & $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$	Eroob fruit						0.021
AwarysOne 379 (35.3) 77 (25.3) 99 (36.5) 94 (35.3) 110 (41.2) Fresh vegetables 0.333 MarysOner 688 (64.5) 189 (71.1) 170 (63.4) 172 (64.7) 157 (58.8) 0.333 AlwaysOften 974 (91.3) 224 (91.7) 238 (88.8) 248 (93.2) 244 (91.4) 0.333 Sometimes/Rarely or never 93 (8.7) 22 (8.3) 30 (11.2) 18 (6.8) 23 (8.6) 0.002 Eat Eggs 0.002 300 (11.2) 18 (6.8) 124 (46.4) 0.564 Sometimes/Rarely or never 419 (39.3) 82 (30.8) 111 (41.4) 102 (38.3) 124 (46.4) Eat milk products 0.564 33 (50.0) 28 (10.4) 33 (12.4) 23 (8.6) 23 (8.6) Sometimes/Rarely or never 955 (89.5) 28 (10.5) 240 (89.6) 233 (87.6) 244 (91.4) 23 (8.6) Sometimes/Rarely or never 955 (89.5) 28 (10.5) 240 (89.6) 233 (87.6) 244 (91.4) 23 (8.6) Sometimes/Rarely or never 399 (37.4) 133 (50.0) 102 (38.1)	Fresh Iruit	070 (0F F)	77 (00.0)	08 (26 6)	04 (25.2)	110 (41 0)	0.031
	Always/Offen	379 (35.5)	77 (28.9)	98 (36.6)	94 (35.3)	110 (41.2)	
	Sometimes/Rarely or never	688 (64.5)	189 (71.1)	170 (63.4)	172 (64.7)	157 (58.8)	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Fresh vegetables						0.333
$ \begin{array}{c c c c c c c } Sometimes/Rarely or never & 93 (8.7) & 22 (8.3) & 30 (11.2) & 18 (6.8) & 23 (8.6) \\ \hline Eat Eggs & & & & & & & & & & & & & & & & & & $	Always/Often	974 (91.3)	244 (91.7)	238 (88.8)	248 (93.2)	244 (91.4)	
Lat Eggs0.002Always/Often648 (60.7)184 (69.2)157 (58.6)164 (61.7)143 (53.6)Sometimes/Rarely or never419 (39.3)82 (30.8)111 (41.4)102 (38.3)142 (46.4)Always/Often112 (10.5)28 (10.5)28 (10.4)33 (12.4)23 (8.6)0.664Sometimes/Rarely or never955 (89.5)28 (10.5)28 (10.4)33 (12.4)23 (8.6)0.664Always/Often668 (62.6)133 (50.0)166 (61.9)181 (68.0)188 (70.4)0.664Sometimes/Rarely or never399 (37.4)133 (50.0)102 (38.1)85 (32.0)79 (29.6)0.001Always/Often668 (62.6)133 (50.0)110 (43.1)151 (66.6)0.0010.001Sometimes/Rarely or never590 (55.3)182 (68.4)157 (58.6)135 (50.8)114 (43.4)0.055Always/Often548 (51.4)119 (44.7)144 (53.7)149 (56.0)136 (50.9)0.055Always/Often519 (48.6)137 (55.3)124 (46.3)117 (44.0)131 (49.1)0.055Always/Often519 (48.6)147 (55.3)124 (46.3)117 (44.0)131 (49.1)0.055Be products </td <td>Sometimes/Rarely or never</td> <td>93 (8.7)</td> <td>22 (8.3)</td> <td>30 (11.2)</td> <td>18 (6.8)</td> <td>23 (8.6)</td> <td></td>	Sometimes/Rarely or never	93 (8.7)	22 (8.3)	30 (11.2)	18 (6.8)	23 (8.6)	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Eat Eggs						0.002
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Always/Often	648 (60.7)	184 (69.2)	157 (58.6)	164 (61.7)	143 (53.6)	
Eat milk products0.564Always/Often112 (10.5)28 (10.5)28 (10.4)33 (12.4)23 (8.6)Sometimes/Rarely or never955 (89.5)238 (89.5)240 (89.6)233 (87.6)244 (91.4)Eat meat	Sometimes/Rarely or never	419 (39.3)	82 (30.8)	111 (41.4)	102 (38.3)	124 (46.4)	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Eat milk products						0.564
Sometimes/Rarely or never955 (89.5)238 (89.5)240 (89.6)233 (87.6)244 (91.4)Eat meat	Always/Often	112 (10.5)	28 (10.5)	28 (10.4)	33 (12.4)	23 (8.6)	
Eat meat Construction of the form of the for	Sometimes/Barely or never	955 (89.5)	238 (89.5)	240 (89 6)	233 (87 6)	244 (91 4)	
Always/Often668 (62.6)133 (50.0)166 (61.9)181 (68.0)188 (70.4)Sometimes/Rarely or never399 (37.4)133 (50.0)102 (38.1)85 (32.0)79 (29.6)Eat fish	Eat meat		200 (0010)	210 (0010)	200 (0110)	2(0)	~0.001
Always Orient 100 (02.0) 100 (02.0) 100 (01.0) 101 (00.0) 100 (02.4) Sometimes/Rarely or never 399 (37.4) 133 (50.0) 102 (38.1) 85 (32.0) 79 (29.6) Eat fish	Always/Offen	668 (62 6)	133 (50 0)	166 (61 9)	181 (68.0)	188 (70 4)	
Schedines/Rately of never 399 (37.4) 133 (30.0) 102 (30.1) 303 (32.0) 79 (23.0) Eat fish Always/Often 477 (44.7) 84 (31.6) 111 (41.4) 131 (49.2) 151 (56.6) Sometimes/Rarely or never 590 (55.3) 182 (68.4) 157 (58.6) 135 (50.8) 114 (43.4) Eat bean products 0.055 Always/Often 548 (51.4) 119 (44.7) 144 (53.7) 149 (56.0) 136 (50.9) Sometimes/Rarely or never 519 (48.6) 147 (55.3) 124 (46.3) 117 (44.0) 131 (49.1) Physical examination BMI (kg/m ²) 20.22 ± 3.53 20.14 ± 3.24 20.28 ± 3.75 20.31 ± 3.50 20.17 ± 3.63 0.937 SBP (mmHg) 142.54 ± 22.04 142.89 ± 22.29 142.98 ± 21.95 143.08 ± 22.27 141.22 ± 21.72 0.732 DBP (mmHq) 78.68 ± 11.52 78.86 ± 11.66 78.45 ± 10.76 79.67 ± 11.34 77.76 ± 12.24 0.281	Sometimes/Barely or payor	200 (27.4)	133 (50.0)	100 (01.3)	85 (22.0)	70 (20 6)	
Colom Always/Often 477 (44.7) 84 (31.6) 111 (41.4) 131 (49.2) 151 (56.6) Sometimes/Rarely or never 590 (55.3) 182 (68.4) 157 (58.6) 135 (50.8) 114 (43.4) Eat bean products 0.055 Always/Often 548 (51.4) 119 (44.7) 144 (53.7) 149 (56.0) 136 (50.9) Sometimes/Rarely or never 519 (48.6) 147 (55.3) 124 (46.3) 117 (44.0) 131 (49.1) Physical examination BMI (kg/m ²) 20.22 ± 3.53 20.14 ± 3.24 20.28 ± 3.75 20.31 ± 3.50 20.17 ± 3.63 0.937 SBP (mmHg) 142.54 ± 22.04 142.89 ± 22.29 142.98 ± 21.95 143.08 ± 22.27 141.22 ± 21.72 0.732 DBP (mmHq) 78.68 ± 11.52 78.86 ± 11.66 78.45 ± 10.76 79.67 ± 11.34 77.76 ± 12.24 0.281		399 (37.4)	133 (50.0)	102 (36.1)	85 (32.0)	79 (29.0)	0.001
Always/Utten $4/7 (44.7)$ $84 (31.6)$ $111 (41.4)$ $131 (49.2)$ $151 (56.6)$ Sometimes/Rarely or never $590 (55.3)$ $182 (68.4)$ $157 (58.6)$ $135 (50.8)$ $114 (43.4)$ Eat bean products0.055Always/Often $548 (51.4)$ $119 (44.7)$ $144 (53.7)$ $149 (56.0)$ $136 (50.9)$ Sometimes/Rarely or never $519 (48.6)$ $147 (55.3)$ $124 (46.3)$ $117 (44.0)$ $131 (49.1)$ Physical examinationEMI (kg/m ²) 20.22 ± 3.53 20.14 ± 3.24 20.28 ± 3.75 20.31 ± 3.50 20.17 ± 3.63 0.937 SBP (mmHg) 142.54 ± 22.04 142.89 ± 22.29 142.98 ± 21.95 143.08 ± 22.27 141.22 ± 21.72 0.732 DBP (mmHq) 78.68 ± 11.52 78.86 ± 11.66 78.45 ± 10.76 79.67 ± 11.34 77.76 ± 12.24 0.281	Eat fish						<0.001
Sometimes/Rarely or never 590 (55.3) 182 (68.4) 157 (58.6) 135 (50.8) 114 (43.4) Eat bean products 0.055 Always/Often 548 (51.4) 119 (44.7) 144 (53.7) 149 (56.0) 136 (50.9) Sometimes/Rarely or never 519 (48.6) 147 (55.3) 124 (46.3) 117 (44.0) 131 (49.1) Physical examination BMI (kg/m ²) 20.22 \pm 3.53 20.14 \pm 3.24 20.28 \pm 3.75 20.31 \pm 3.50 20.17 \pm 3.63 0.937 SBP (mmHg) 142.54 \pm 22.04 142.89 \pm 22.29 142.98 \pm 21.95 143.08 \pm 22.27 141.22 \pm 21.72 0.732 DBP (mmHq) 78.68 \pm 11.52 78.86 \pm 11.66 78.45 \pm 10.76 79.67 \pm 11.34 77.76 \pm 12.24 0.281	Always/Offen	477 (44.7)	84 (31.6)	111 (41.4)	131 (49.2)	151 (56.6)	
0.055 Always/Often 548 (51.4) 119 (44.7) 144 (53.7) 149 (56.0) 136 (50.9) Sometimes/Rarely or never 519 (48.6) 147 (55.3) 124 (46.3) 117 (44.0) 131 (49.1) Physical examination BMI (kg/m ²) 20.22 ± 3.53 20.14 ± 3.24 20.28 ± 3.75 20.31 ± 3.50 20.17 ± 3.63 0.937 SBP (mmHg) 142.54 ± 22.04 142.89 ± 22.29 142.98 ± 21.95 143.08 ± 22.27 141.22 ± 21.72 0.732 DBP (mmHq) 78.68 ± 11.52 78.86 ± 11.66 78.45 ± 10.76 79.67 ± 11.34 77.76 ± 12.24 0.281	Sometimes/Rarely or never	590 (55.3)	182 (68.4)	157 (58.6)	135 (50.8)	114 (43.4)	
Always/Often 548 (51.4) 119 (44.7) 144 (53.7) 149 (56.0) 136 (50.9) Sometimes/Rarely or never 519 (48.6) 147 (55.3) 124 (46.3) 117 (44.0) 131 (49.1) Physical examination 500 (48.6) 20.22 ± 3.53 20.14 ± 3.24 20.28 ± 3.75 20.31 ± 3.50 20.17 ± 3.63 0.937 SBP (mmHg) 142.54 ± 22.04 142.89 ± 22.29 142.98 ± 21.95 143.08 ± 22.27 141.22 ± 21.72 0.732 DBP (mmHg) 78.68 ± 11.52 78.86 ± 11.66 78.45 ± 10.76 79.67 ± 11.34 77.76 ± 12.24 0.281	Eat bean products						0.055
Sometimes/Rarely or never 519 (48.6) 147 (55.3) 124 (46.3) 117 (44.0) 131 (49.1) Physical examination BMI (kg/m ²) 20.22 ± 3.53 20.14 ± 3.24 20.28 ± 3.75 20.31 ± 3.50 20.17 ± 3.63 0.937 SBP (mmHg) 142.54 ± 22.04 142.89 ± 22.29 142.98 ± 21.95 143.08 ± 22.27 141.22 ± 21.72 0.732 DBP (mmHg) 78.68 ± 11.52 78.86 ± 11.66 78.45 ± 10.76 79.67 ± 11.34 77.76 ± 12.24 0.281	Always/Often	548 (51.4)	119 (44.7)	144 (53.7)	149 (56.0)	136 (50.9)	
Physical examination BMI (kg/m ²) 20.22 ± 3.53 20.14 ± 3.24 20.28 ± 3.75 20.31 ± 3.50 20.17 ± 3.63 0.937 SBP (mmHg) 142.54 ± 22.04 142.89 ± 22.29 142.98 ± 21.95 143.08 ± 22.27 141.22 ± 21.72 0.732 DBP (mmHg) 78.68 ± 11.52 78.86 ± 11.66 78.45 ± 10.76 79.67 ± 11.34 77.76 ± 12.24 0.281	Sometimes/Rarely or never	519 (48.6)	147 (55.3)	124 (46.3)	117 (44.0)	131 (49.1)	
BMI (kg/m ²) 20.22 ± 3.53 20.14 ± 3.24 20.28 ± 3.75 20.31 ± 3.50 20.17 ± 3.63 0.937 SBP (mmHg) 142.54 ± 22.04 142.89 ± 22.29 142.98 ± 21.95 143.08 ± 22.27 141.22 ± 21.72 0.732 DBP (mmHg) 78.68 ± 11.52 78.86 ± 11.66 78.45 ± 10.76 79.67 ± 11.34 77.76 ± 12.24 0.281	Physical examination						
SBP (mmHg) 142.54 ± 22.04 142.89 ± 22.29 142.98 ± 21.95 143.08 ± 22.27 141.22 ± 21.72 0.732 DBP (mmHg) 78.68 ± 11.52 78.86 ± 11.66 78.45 ± 10.76 79.67 ± 11.34 77.76 ± 12.24 0.281	BMI (kg/m²)	20.22 ± 3.53	20.14 ± 3.24	20.28 ± 3.75	20.31 ± 3.50	20.17 ± 3.63	0.937
DBP (mmHq) 78.68 ± 11.52 78.86 ± 11.66 78.45 ± 10.76 79.67 ± 11.34 77.76 + 12.24 0.281	SBP (mmHg)	142.54 ± 22.04	142.89 ± 22.29	142.98 ± 21.95	143.08 ± 22.27	141.22 ± 21.72	0.732
	DBP (mmHg)	78.68 ± 11.52	78.86 ± 11.66	78.45 ± 10.76	79.67 ± 11.34	77.76 ± 12.24	0.281

(Continued on following page)

Characteristics	All subjects		Serum uric acid	quartiles (µmol/L)		<i>p</i> -value
	(N = 1,067)	Q1 (N = 266)	Q2 (N = 268)	Q3 (N = 266)	Q4 (N = 267)	
Biochemical parameters						
Blood Urea Nitrogen (mmol/L) ^a	6.67 ± 2.25	6.07 ± 1.60	6.25 ± 1.80	6.74 ± 2.11	7.63 ± 2.92	< 0.001 ^{e, f, h, i}
Plasma creatinine (mmol/L) ^b	80.0 (66.0–100.0)	68.0 (55.0–79.0)	75.5 (62.0–92.0)	87.0 (74.0–105.3)	97.0 (81.0–125.0)	< 0.001 ^{d–i}
Plasma glucose (mmol/L)	5.43 ± 1.89	5.28 ± 2.07	5.28 ± 1.67	5.52 ± 2.03	5.62 ± 1.75	0.089
Total cholesterol (mmol/L) ^a	3.49 ± 1.28	3.44 ± 1.04	3.48 ± 1.28	3.56 ± 1.34	3.48 ± 1.42	0.691
HDL cholesterol (mmol/L)	1.16 ± 0.32	1.14 ± 0.33	1.16 ± 0.30	1.16 ± 0.32	1.19 ± 0.33	0.441
LDL cholesterol (mmol/L) ^a	2.02 ± 0.77	1.81 ± 0.63	1.99 ± 0.75	2.11 ± 0.73	2.18 ± 0.91	< 0.001 ^{e, f}
Triglyceride (mmol/L) ^b	1.08 (0.84-1.66)	0.94 (0.76-1.24)	1.09 (0.87-1.49)	1.19 (0.88–1.88)	1.20 (0.89–2.25)	< 0.001 ^{d-f, h}
Disease History						
Hypertension	161 (15.1)	37 (13.8)	42 (15.7)	45 (16.9)	37 (14.0)	0.713
Diabetes mellitus	16 (1.5)	3 (1.1)	7 (2.6)	4 (1.5)	2 (0.8)	0.388
Heart diseases	63 (5.9)	23 (8.6)	13 (4.9)	16 (6.0)	11 (4.2)	0.128
Stroke or CVD	36 (3.4)	11 (4.1)	10 (3.7)	5 (1.9)	10 (3.8)	0.486
Cancer ^c	2 (0.2)	0 (0.0)	1 (0.4)	0 (0.0)	1 (0.4)	1.00
Chronic nephritis ^c	2 (0.2)	1 (0.4)	0 (0.0)	1 (0.4)	0 (0.0)	0.374

TABLE 1 | (Continued) Baseline characteristics of all study participants according to serum uric acid quartiles (Chinese Longitudinal Health Longevity Survey, China, 2008–2018).

Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; HDL, high density lipoprotein; LDL, low density lipoprotein; CVD, cerebrovascular disease; Q1, 1st quartile; Q2, 2nd quartile; Q3, 3rd quartile; Q4, 4th quartile.

Data are presented as mean ± SD or mean (IQR) for continuous variables and n (%) for categorical variables.

^aWelch test due to uneven variance.

^bKruskal-Wallis test.

^cFisher's exact probability test. ANOVA or Kruskal-Wallis test with post hoc test were performed to compare the potencial differences between quartiles of SUA level.

^dStatistical significance between Q1 level group and Q2 level group.

^eStatistical significance between Q1 level group and Q3 level group.

^fStatistical significance between Q1 level group and Q4 level group.

^gStatistical significance between Q2 level group and Q3 level group.

^hStatistical significance between Q2 level group and Q4 level group.

¹Statistical significance between Q3 level group and Q4 level group. Cut points for SUA quartile grouping being male: <241.30, 241.30–303.90, 303.90–355.80 and \geq 355.80 µmol/L; female: <201.65, 201.65–245.75, 245.75–301.70 and \geq 301.70 µmol/L.

Bold p-values indicated p < 0.05.

HR (95%C) P-value PR (95%C) P-value	Quartiles	Individuals	Events (%)	Person-years	Model 1		Model 2		Model 3		Model 4	
All subjects All subjects 266 137 (51.12) 1545.58 0.90 (0.71-1.14) 0.388 1.16 (0.91-1.48) 0.237 1.15 (0.90-1.46) 0.279 1.08 (0.84) Quartile 1 268 137 (51.12) 1545.58 0.90 (0.71-1.14) 0.388 1.16 (0.91-1.48) 0.237 1.15 (0.90-1.45) 0.279 1.08 (0.84) Quartile 2 268 144 (53.73) 1440.33 1.03 (0.82-1.30) 0.809 1.12 (0.89-1.43) 0.233 1.14 (0.90-1.45) 0.273 1.12 (0.88) Quartile 2 266 138 (51.88) 1.145 References References References 1.34 (1.05-1.59) 0.273 1.12 (0.89-1.45) 0.273 1.12 (0.89) 1.34 (1.05) 0.273 1.12 (0.89) 1.34 (1.05) 0.273 1.12 (0.89) 1.34 (1.05) 0.273 1.12 (0.89) 1.34 (1.05) 0.273 1.12 (0.89) 1.34 (1.05) 0.293 1.34 (1.05) 0.293 1.34 (1.05) 0.273 1.12 (0.89) 1.34 (1.05) 0.293 1.34 (1.05) 0.293 1.34 (1.05) 0.293 1.34 (1.05) 0.293 1.34 (1.05) 0.293 1.34 (1.05) 0.293 1.34 (1.05)					HR (95%CI)	<i>p</i> -value	HR (95%CI)	p-value	HR (95%CI)	<i>p</i> -value	HR (95%CI)	<i>p</i> -value
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	All subjects											
Quartile 2 268 144 (53.73) 1440.33 1.03 (0.82-1.30) 0.809 1.12 (0.89-1.45) 0.273 1.12 (0.86 Quartile 3 266 138 (51.88) 1415 References References References 1.43 (1.13-1.80) 0.203 1.12 (0.88) Quartile 3 266 138 (51.88) 1415 References References 1.44 (1.12-1.78) 0.333 1.14 (0.90-1.45) 0.203 1.34 (1.06) Males Quartile 1 (<241.30)	Quartile 1	266	137 (51.12)	1545.58	0.90 (0.71–1.14)	0.388	1.16 (0.91–1.48)	0.237	1.15 (0.90-1.46)	0.279	1.08 (0.84–1.39)	0.557
Quartile 3 266 138 (51.88) 1415 References References <th< td=""><td>Quartile 2</td><td>268</td><td>144 (53.73)</td><td>1440.33</td><td>1.03 (0.82-1.30)</td><td>0.809</td><td>1.12 (0.89–1.43)</td><td>0.333</td><td>1.14 (0.90-1.45)</td><td>0.273</td><td>1.12 (0.88–1.43)</td><td>0.358</td></th<>	Quartile 2	268	144 (53.73)	1440.33	1.03 (0.82-1.30)	0.809	1.12 (0.89–1.43)	0.333	1.14 (0.90-1.45)	0.273	1.12 (0.88–1.43)	0.358
Quartile 4 267 159 (60.00) 1198.50 1.38 (1.10-1.73) 0.006 1.41 (1.12-1.78) 0.004 1.43 (1.13-1.80) 0.003 1.34 (1.06 Males Males 1.41 57 (50.00) 695.33 1.04 ($0.71-1.51$) 0.855 1.20 ($0.79-1.81$) 0.389 1.19 ($0.77-1.83$) 0.429 1.33 (0.89 Males Quartile 1 (<241.30) 114 57 (50.00) 695.33 1.04 ($0.71-1.51$) 0.855 1.20 ($0.79-1.81$) 0.389 1.19 ($0.77-1.83$) 0.201 1.24 (0.80 Quartile 2 (241.30) 116 50 (43.10) 708.67 0.896 ($.50-1.31$) 0.547 1.01 ($0.67-1.53$) 0.2701 1.24 (0.80 Quartile 2 (241.30) 114 58 (50.88) 575.25 1.26 ($0.86-1.83$) 0.221 1.20 ($0.86-1.92$) 0.221 1.30 ($0.86-1.97$) 0.219 1.34 (0.80 Cuartile 4 (<5355.80) 114 58 (50.88) 575.25 1.26 ($0.86-1.83$) 0.221 1.20 ($0.86-1.92$) 0.221 1.34 (0.80 <	Quartile 3	266	138 (51.88)	1415	References		References		References		References	
Males Males <th< td=""><td>Quartile 4</td><td>267</td><td>159 (60.00)</td><td>1198.50</td><td>1.38 (1.10-1.73)</td><td>0.006</td><td>1.41 (1.12–1.78)</td><td>0.004</td><td>1.43 (1.13–1.80)</td><td>0.003</td><td>1.34 (1.06–1.71)</td><td>0.016</td></th<>	Quartile 4	267	159 (60.00)	1198.50	1.38 (1.10-1.73)	0.006	1.41 (1.12–1.78)	0.004	1.43 (1.13–1.80)	0.003	1.34 (1.06–1.71)	0.016
Quartile 1 (<241.30)	Males											
Quartile 2 (241.30-303.90) 116 50 (43.10) 708.67 0.89 (0.60-1.31) 0.547 1.01 (0.67-1.53) 0.970 1.09 (0.71-1.66) 0.701 1.24 (0.80) Quartile 2 (241.30-303.90) 115 51 (44.35) 637.08 References References References References References References 1.24 (0.80) Quartile 3 (303.90-355.80) 115 51 (44.35) 637.08 References 0.231 1.29 (0.86-1.92) 0.221 1.30 (0.86-1.97) 0.219 1.34 (0.88) Remailes 0.uartile 4 (>535.80) 114 58 (50.88) 575.25 1.26 (0.86-1.1.83) 0.231 1.29 (0.86-1.92) 0.221 1.30 (0.86-1.97) 0.219 1.34 (0.88) Females 0.uartile 1 (<201.65)	Quartile 1 (<241.30)	114	57 (50.00)	695.33	1.04 (0.71–1.51)	0.855	1.20 (0.79–1.81)	0.389	1.19 (0.77–1.83)	0.429	1.39 (0.89–2.17)	0.148
Quartile 3 (303:90-355.80) 115 51 (44.35) 637.08 References References References References Quartile 4 (>355.80) 114 58 (50.88) 575.25 1.26 (0.86-1.83) 0.231 1.29 (0.86-1.92) 0.221 1.30 (0.86-1.97) 0.219 1.34 (0.88) Females 0.231 126 (0.86-1.83) 0.231 1.29 (0.86-1.92) 0.219 1.34 (0.88) Cuartile 4 (>355.80) 152 850.25 0.82 (0.61-1.12) 0.208 1.13 (0.83-1.55) 0.435 1.11 (0.81-1.52) 0.516 1.02 (0.73) Quartile 1 (<201.65)	Quartile 2 (241.30-303.90)	116	50 (43.10)	708.67	0.89 (0.60-1.31)	0.547	1.01 (0.67-1.53)	0.970	1.09 (0.71–1.66)	0.701	1.24 (0.80-1.92)	0.330
Quartile 4 (>355.80) 114 58 (50.88) 575.25 1.26 (0.86-1.83) 0.231 1.29 (0.86-1.92) 0.221 1.30 (0.86-1.97) 0.219 1.34 (0.88) Females Cuartile 1 (<201.65)	Quartile 3 (303.90–355.80)	115	51 (44.35)	637.08	References		References		References		References	
Females Females Ouartile 1 (<201.65)	Quartile 4 (>355.80)	114	58 (50.88)	575.25	1.26 (0.86–1.83)	0.231	1.29 (0.86–1.92)	0.221	1.30 (0.86–1.97)	0.219	1.34 (0.88–2.04)	0.176
Quartile 1 (<201.65) 152 80 (51.95) 850.25 0.82 (0.61-1.12) 0.208 1.13 (0.83-1.55) 0.435 1.11 (0.81-1.52) 0.516 1.02 (0.73) Quartile 2 (201.65-245.75) 152 94 (61.84) 731.67 1.15 (0.86-1.54) 0.349 1.21 (0.90-1.63) 0.202 1.19 (0.88-1.60) 0.256 1.09 (0.81) Quartile 2 (201.65-245.75) 151 87 (57.62) 777.92 References References References References References References 1.414 forences References 1.414 forences	Females											
Quartile 2 (201.65–245.75) 152 94 (61.84) 731.67 1.15 (0.86–1.54) 0.349 1.21 (0.90–1.63) 0.202 1.19 (0.88–1.60) 0.256 1.09 (0.81-1.03) Quartile 3 (245.75–301.70) 151 87 (57.62) 777.92 References <	Quartile 1 (<201.65)	152	80 (51.95)	850.25	0.82 (0.61–1.12)	0.208	1.13 (0.83-1.55)	0.435	1.11 (0.81–1.52)	0.516	1.02 (0.73-1.42)	0.916
Quartile 3 (245.75–301.70) 151 87 (57.62) 777.92 References Re	Quartile 2 (201.65–245.75)	152	94 (61.84)	731.67	1.15 (0.86–1.54)	0.349	1.21 (0.90-1.63)	0.202	1.19 (0.88–1.60)	0.256	1.09 (0.81–1.49)	0.564
Outorefile A (2004 20) 452 404 (68 80) 800 800 800 800 144 4 4 68) 0 000 4 52 (4 12 0 40) 152 (4 12 0 41) 0 000 1 4 14 (10 0	Quartile 3 (245.75–301.70)	151	87 (57.62)	777.92	References		References		References		References	
	Quartile 4 (>301.70)	153	101 (66.89)	623.25	1.47 (1.11–1.96)	0.008	1.57 (1.17–2.10)	0.003	1.57 (1.17–2.11)	0.003	1.41 (1.03–1.92)	0.033

confounding biomarkers in the model, which were selected a priori based on previous studies examining risk factors for serum acid levels and all-cause mortality. uric The sociodemographic information included age, sex (male/ female), residence (rural/other) and economic income (low/high). Health characteristics included lifestyle and history of chronic diseases. Lifestyle characteristics contained smoking (yes/no), drinking (yes/no), physical activity (current or former/none) and diet (frequency of consuming fresh fruit, vegetables, eggs, milk products, meat, fish and food made from beans). After the household interview, all participants were asked to undergo anthropometric measurements, which included systolic blood pressure (mmHg), diastolic blood pressure (mmHg) and body mass index (kg/m²). History of chronic disease including self-reported and/or hospital diagnosed hypertension, diabetes, heart disease, stroke or cerebrovascular disease and chronic nephritis. Blood biochemistry tests were analyzed in this study, included BUN (mmol/L), plasma creatinine (mmol/L), SUA (µmol/ L), plasma glucose (mmol/L), TC (mmol/L), HDL-C (mmol/ L), LDL-C (mmol/L), TG (mmol/L).

Statistical Analysis

Continuous variables were presented as mean (standard deviation, SD) or median (interquartile range, IQR), and categorical variables were presented as counts (%).

For continuous variables that followed normal distribution, we used two independent sample t-test and ANOVA to compare the characteristics of participants in two and multiple groups, respectively. Tukey's post-hoc test or Games-Howell post-hoc test was used to conduct pairwise comparisons for multiple groups. For the continuous variables with skewed distribution, Mann-Whitney U test and Kruskal-Wallis test with Dunn post-hoc test were used to compare the difference between two groups and multiple groups, respectively. Characteristics of the two and multiple groups were compared using chi-square test for categorical variables.

Multivariate Cox proportional hazards models were used to investigate relationships between SUA with all-cause mortality, using the third quartile (Q3) of SUA levels as a reference, and the results are presented as hazard ratios (HRs) and 95% confidence intervals (CIs). We performed analyses of the association between SUA and all-cause mortality by sex using four models based on previous studies as follows (8, 9, 25): Model 1 was crude; Model 2 was adjusted for age, category of residence, economic income, smoke, drink, physical activity and diet; Model 3 was further adjusted for SBP, DBP, BMI and history of chronic diseases; Model 4 was further adjusted for BUN, plasma creatinine, plasma glucose, TC, HDL cholesterol, LDL cholesterol and TG. Furthermore, the survival probability according to diagnostic values of hyperuricemia were calculated using the Kaplan-Meier curves, and the log-rank test was performed to analyze differences of all-cause mortality among quartiles of SUA. The multivariable Cox regression model's discriminative

Bold p-values indicated p < 0.05

confidence interval.







mellitus, heart diseases, stroke or cerebrovascular diseases, and chronic nephritis; and blood urea nitrogen, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglyceride, total cholesterol, plasma creatinine and plasma glucose. Abbreviations: Q1, 1st quartile; Q2, 2nd quartile; Q3, 3rd quartile; Q4, 4th quartile; HR, Hazard ratio; CI, confidence interval.

performance was assessed by time-dependent receiver operating characteristic (ROC) curves and area under the curve (AUC) analysis.

In addition, subgroup analyses and their interactions were conducted to further explore whether gender would modify the relationship between SUA levels and all-cause mortality. Furthermore, multivariate Cox regression models with restricted cubic splines (RCS) methods were performed to explore the potentially non-linear relationship between SUA level and hazard ratio of all-cause mortality, using SUA level as a continuous variable. To balance best fit and overfitting in the main splines for all-cause mortality, the optimal model is



selected based on the knot (ranging from 3 to 10) corresponding to the lowest value of the Akaike Information Criterion (AIC). In present study, we used restricted cubic splines methods with three knots to analyze the non-linear relationship.

Sensitivity analyses were performed to evaluate the robustness of our results: 1) using diagnostic values for clinically defined hyperuricemia by gender (male: 420 μ mol/L; female: 360 μ mol/L) instead of quartiles; 2) We excluded participants who were younger than 80 years old and further explored the relationship between SUA levels and all-cause mortality in the oldest-old adults.

The statistical analysis was performed using the R 4.0.3 Statistical Package (The R foundation for Statistical Computing). A two-sided p < 0.05 was considered to indicate statistical significance.

RESULT

Baseline Characteristics

Demographics, lifestyle, diet, history of chronic disease, and biochemical characteristics of all study participants were compared according to SUA level quartiles (**Table 1**). In brief, the mean age of study population was 84.84 years and 57.0% participants were female (n = 608). Participants who had higher SUA level tended to be older, lived in city or town areas, had higher income, drink alcohol, and eat meat and fish. In addition, participants with higher SUA levels had high levels of BUN, plasma creatinine, LDL-C and TG. The baseline characteristics of participants who remained in the cohort and were lost from the cohort due to lost to follow-up or death are summarized in **Supplementary Tables S1, S2**. The sex-specific baseline characteristics according to diagnostic values for hyperuricemia (male: 420 µmol/L; female: 360 µmol/L) are shown in **Supplementary Table S3**.

Association of Serum Uric Acid and All-Cause Mortality

Table 2 presented the association between the level of SUA and allcause mortality in all study population and sex-specific population. In the general population, the highest quartile (Q4) of SUA levels was associated with increased all-cause mortality in univariate model (Model 1: HR: 1.38; 95% CI: 1.10-1.73), when compared with the third quartile of SUA levels (Q3). This relationship remained statistically significant in the multivariate model (model 4) after adjusting for socio-demographic, health characteristics and clinical biochemical markers (HR: 1.34; 95% CI: 1.06-1.71). No statistically significant results were observed between SUA levels and all-cause mortality in men, neither in the crude model nor in the full-adjusted model. It was noteworthy that the significantly positive association between SUA levels and all-cause mortality still persisted in the female population. Compared with Q3 of SUA levels, the multivariate adjusted HR (model 4) for all-cause mortality was 1.41 (95% CI, 1.03-1.92) for Q4.

Survival Analysis

The Kaplan-Meier survival curves for all-cause mortality according to quartiles of serum uric acid are illustrated in **Figure 1**. In female participants, the survival probability between participants in each of the SUA quartiles show significantly difference (log-rank p < 0.001) (**Figure 1B**). However, in male participants, the survival probability between participants in each of the SUA quartiles did not show significantly difference (log-rank p = 0.320) (**Figure 1A**).

Time-Dependent ROC Analysis of Predictive Accuracy for All-Cause Mortality

Time-dependent ROC analysis was conducted to compare the ability of the Model 4 to predict all-cause mortality between male and female. The AUC values of female in the total followup time were greater than those of male, which showed relatively good predictive accuracy in female (Figure 1C).

Subgroup Analysis

Subgroup analysis showed that the interaction *p*-value for gender was 0.011, which indicated that the association between SUA levels and all-cause mortality was significantly different by gender after adjusting for a range of covariates (**Figure 2**).

A Non-Linear Relationship Between Serum Uric Acid and All-Cause Mortality

To further evaluate a possible non-linear relationship, restricted cubic spline was further performed to investigate the association between all-cause mortality and SUA on a continuous scale. Consistent with the results shown in **Table 2**, the multivariate Cox regression models with restricted cubic splines methods indicated that the relationship between serum uric acid with all-cause mortality was U shaped both in male and female (*P* for non-linear<0.05), and the lowest risk was observed to be within the third quartile SUA levels for men and women, respectively (**Figure 3**). Low and high levels of SUA were associated with an increased risk of all-cause mortality.

Sensitivity Analysis

The relationship between serum SUA levels and all-cause mortality remained consistent in sensitivity analyses after using clinically defined cut-off values for SUA levels (Supplementary Table S4). In female participants, compared to the participants in lower than 360 µmol/L of serum uric acid, those in higher than 360 µmol/L of serum uric acid were associated with increased all-cause mortality in full-adjusted model (Model 4: HR, 1.65; 95% CI, 1.13-2.41). However, in male participants, compared to the participants in lower than 420 µmol/L of serum uric acid, those in higher than 420 µmol/L of serum uric acid were not associated with increased all-cause mortality in univariable and multivariate model. The KM survival curves and time-dependent ROC analysis of all-cause mortality according to the SUA clinical diagnostic reference value (male: 420 µmol/L; female: 360 µmol/L) are shown in Supplementary Figures S2, S3, which also showed similar results. In addition, it is noteworthy that the highest quartile of SUA levels (Q4) was also found to be associated with an increased risk of all-cause mortality compared to the reference SUA levels (Q3) in the study population confined to oldest-old adults. Meanwhile, the lowest quartile of SUA levels (Q1) was associated with an increased risk of all-cause mortality, which might also confirm that the U-shaped relationship between SUA levels and all-cause mortality risk also persisted in the oldest-old subjects (Supplementary Table S5).

DISCUSSION

This study revealed a potential causal association between hyperuricemia and 10-year all-cause mortality in the Chinese aging population. Our study in the aging population also supported the common consensus that hyperuricemia might increase all-cause mortality. It was noteworthy that this finding was gender-specific, and the association was particularly pronounced among the female older population. In addition, the present study observed non-linear associations between SUA levels and all-cause mortality in both older males and females.

To date, current epidemiological studies on the relationship between SUA levels and all-cause mortality among older adults have been rarely investigated and available evidence is inconsistent. Several studies provided evidence to support the predictive value and risk effects of hyperuricemia or higher SUA levels on all-cause mortality in the aging population (12, 13, 26). Conversely, few previous studies failed to confirm the associations between hyperuricemia and all-cause mortality in the aging population (21, 27). These controversial findings might be induced partially by the differences in the type of study, the characteristics of the study population (i.e., gender, ethnicity, and study region), sample size, cutoff points of hyperuricemia, and adjustment of confounders (physical activity, diet, history of chronic diseases, blood biochemical indicators and so on). Therefore, we used stepwise models to adjust for various possible confounders. By extensively adjusting for potential confounders and performing gender-stratified analysis, our study provided prospective evidence that hyperuricemia might independently predict all-cause mortality in Chinese older adults.

Consistent with previous observations in the general population, the older men in the present study had significantly higher levels of SUA than the older women, implying that the relationship with all-cause mortality was complex and strongly related to gender. However, there were no definite conclusions about gender differences between hyperuricemia and all-cause mortality, which partly due to differences in the study population. Some previous observations in general adults found that higher SUA levels are more strongly associated with all-cause mortality in women than in men (28, 29). Nevertheless, an observational study using NHANES data in US adults found that high uric acid levels were associated with increased allcause mortality regardless of gender, with a higher risk of allcause mortality in men compared to women (30). However, few studies in healthy adults observed the association of SUA levels with all-cause mortality among men, but not women (31). These inconsistent findings also implied that it is necessary to stratify by gender when investigating the relationship between hyperuricemia and all-cause mortality in older adults.

Most noteworthy, when the all-cause mortality risk was analyzed according to quartiles of uric acid levels, our study demonstrated that the significant association between hyperuricemia and all-cause mortality was only in the female older population, which was consistent with some previous findings in the older population (14, 18, 19). Similar results were found in sensitivity analyses by using clinical cutoffs of dichotomous SUA levels. In addition, there were no statistically significant associations between SUA levels and all-cause mortality in both men and women after adjusting for potential confounders in the recent aged physical examination cohort from Shanghai, China (21). Therefore, the non-significant relationship found in older men in this study also seemed not abnormal. This finding might be attributed to the older age of the study population and the lower proportion of males with hyperuricemia in this study. In addition, most studies had shown that males with hyperuricemia or abnormal uric acid levels developed diseases such as kidney and liver function injury concentrated in the age range from 40 to 60 years, and then increase the risk of disease-related mortality and all-cause mortality (32–36). These reasons might potentially explain the non-significant association of hyperuricemia in older males on all-cause mortality that contradicted previous literature published in the general population. The current findings not only extend the scope of the study population exploring the relationship between hyperuricemia and all-cause mortality, but also provide new longitudinal evidence for exploring these associations in Chinese older adults. Therefore, future preventive measures related to hyperuricemia should be targeted towards older women as the susceptible population.

Several potential mechanisms could explain the modified role of gender on the relationship between hyperuricemia and all-cause mortality in the aging population. Estrogen levels and the complex metabolic changes associated with menopause might partially explain the gender differences. Estrogens that promote renal excretion of uric acid may keep serum uric acid levels low in women (37). However, one study showed that the level of estrogen that protects against the development of atherosclerosis in postmenopausal women is about half that of men, so hyperuricemia in older women might increase the risk of allcause mortality (38, 39). Menopause has recently been associated with significant increases in SUA levels, implicating the increased risk of hyperuricemia in older women (28, 40). Therefore, our findings could be explained by the hypothesis that postmenopausal women are more susceptible to hyperuricemia than men, and accordingly all-cause mortality is significantly higher in older women than in older men due to the putative pro-oxidant, pro-inflammatory effects of hyperuricemia. The mechanism for hyperuricemia on the increased risk of all-cause mortality in postmenopausal women still need to be further explored. Another potential explanation might be that the LDL cholesterol and total cholesterol levels in women were higher than in men in the current study. The positive relationship between LDL and total cholesterol and hyperuricemia has been studied, especially in women, which is in line with the characteristic profile of higher SUA levels group by gender in this study (41-43).

Furthermore, we found the U-shaped associations between SUA levels and all-cause mortality were observed in both older men and women when SUA levels were analyzed as a continuous variable. A population-based cohort study found a U-shaped association between SUA levels and all-cause mortality risk in the older population aged >65 years in Taiwan, China (44). However, the above studies were not analyzed stratified by gender, which may modify the association between SUA levels and mortality due to gender differences in the distribution of SUA levels. Wu et al. observed a U-shaped non-linear association between SUA levels and all-cause mortality in older men, in agreement with the present study, but failed to provide evidence of a non-linear relationship among older women (14). The above differences of non-linear relationship between SUA levels and allcause mortality risk in the older population depend on the SUA levels of the study population and the sex-specific thresholds for

classifying hyperuricemia. This study also provides new evidence to explore the non-linear relationship between SUA levels and allcause mortality risk in the aging population. In addition, the present study found that whenever SUA levels were analyzed as quartiles or continuous variables, the lowest hazard ratios for allcause mortality were found for SUA levels in the third quartile, which is below the current clinical diagnostic criteria for SUA levels. Therefore, this study highlighted that the normal or optimal level of SUA in older adults should be moderately adjusted in the context of clinical practice. These findings might provide the theoretical evidence and clinical guidelines on primary prevention of hyperuricemia and reducing the burden of various diseases caused by hyperuricemia in older people.

This study has several strengths that overcome some of the limitations of previous studies. Our study collected a Chinese elderly cohort with a long follow-up period covering 7 provinces, which could provide more representative longitudinal evidence on the association between hyperuricemia and all-cause mortality in older adults. Additionally, our study employed gender-stratified analysis to help understand the gender differences between hyperuricemia and all-cause mortality in the Chinese older population. However, several limitations of the present study also should be mentioned. First, the sample size of the older population followed in this study was relatively small because biological sample data of the Chinese oldest old in the CLHLS database were not easily available. We hope that future large population-based cohort studies and experimental studies will further explore the gender-specific associations between hyperuricemia and all-cause mortality in older adults and reveal the underlying mechanisms involved. Second, the population of this study included Chinese older adults, so the findings may be limited by extrapolating to the general population of China and other countries and ethnic. Thirdly, information on the medication use of hyperuricemia and other medications (i.e., diuretics) in the study population was not available during baseline information collection, which might influence the relationship between hyperuricemia and all-cause mortality. Finally, exploration of the potential relationship between serum uric acid levels and cause-specific mortality could not be performed because of the unavailable cause-specific mortality data.

Conclusion

In summary, the relationship between SUA levels and all-cause mortality was modified by gender among Chinese older adults. This longitudinal finding of 10-year follow-up was pronounced in older women participants, but not in older men participants. In addition, our study provided the new epidemiologic evidence that the U-shaped non-linear relationship between SUA levels and allcause mortality was present across gender among Chinese older adults. Further studies are needed to elucidate the actual role of SUA in all-cause mortality among older adults as well as potential biological mechanisms.

ETHICS STATEMENT

The CLHLS study was approved by the Research Ethics Committee of Peking University (IRB00001052-13074). All participants signed written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

YD, ZW, and SW contributed to the study design, data analysis and interpretation, and drafted the manuscript. YL, RW, and SL contributed to the data analysis and interpretation, and critical revision of the manuscript. RC and HC contributed to the administration of the survey and critical revision of the manuscript. CQ, YC, and FH contributed to the design of this study, interpretation of data and critical revision of the manuscript. YC and FH have the primary responsibility for the final content. All authors read and approved the final manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This work was funded by the National Key Research and Development Project, Ministry of Science and Technology of

REFERENCES

- Dong J, Hu LK, Lu YK, Liu YH, Chu X, Yan YX. Association of Serum Uric Acid with the Risk of Developing Hypertension: A Prospective Cohort Study with Mediation Analysis. *Hypertens Res* (2023) 46(2):345–56. doi:10.1038/ s41440-022-01081-1
- He Y, Chen D, Xu JP, Jin J, Wang J, Geng C, et al. Association between Serum Uric Acid and Hypertension in a Large Cross-Section Study in a Chinese Population. J Cardiovasc Dev Dis (2022) 9(10):346. doi:10.3390/jcdd9100346
- Cheang C, Law S, Ren J, Chan W, Wang C, Dong Z. Prevalence of Hyperuricemia in Patients with Severe Obesity and the Relationship between Serum Uric Acid and Severe Obesity: A Decade Retrospective Cross-Section Study in Chinese Adults. *Front Public Health* (2022) 10: 986954. doi:10.3389/fpubh.2022.986954
- Han T, Meng X, Shan R, Zi T, Li Y, Ma H, et al. Temporal Relationship between Hyperuricemia and Obesity, and its Association with Future Risk of Type 2 Diabetes. *Int J Obes (Lond)* (2018) 42(7):1336–44. doi:10.1038/s41366-018-0074-5
- Liu F, Du GL, Song N, Ma YT, Li XM, Gao XM, et al. Hyperuricemia and its Association with Adiposity and Dyslipidemia in Northwest China: Results from Cardiovascular Risk Survey in Xinjiang (CRS 2008-2012). *Lipids Health Dis* (2020) 19(1):58. doi:10.1186/s12944-020-01211-z
- Peng L, Liu L, Ma N, Yang F, Nie C, Yang T, et al. The Dose-Response Relationship of Serum Uric Acid with Dyslipidaemia and its Components: a Cross-Sectional Study of a Chinese Multi-Ethnic Cohort. *Lipids Health Dis* (2022) 21(1):36. doi:10.1186/s12944-022-01647-5
- Gaubert M, Bardin T, Cohen-Solal A, Diévart F, Fauvel JP, Guieu R, et al. Hyperuricemia and Hypertension, Coronary Artery Disease, Kidney Disease: From Concept to Practice. *Int J Mol Sci* (2020) 21(11):4066. doi:10.3390/ ijms21114066
- Yang Y, Zhou W, Wang Y, Zhou R. Gender-specific Association between Uric Acid Level and Chronic Kidney Disease in the Elderly Health Checkup Population in China. *Ren Fail* (2019) 41(1):197–203. doi:10.1080/ 0886022X.2019.1591994
- 9. Hu L, Hu G, Xu BP, Zhu L, Zhou W, Wang T, et al. U-shaped Association of Serum Uric Acid with All-Cause and Cause-specific Mortality in US Adults: A

China (Grant Number 2020YFC2006400), Shanghai Municipal Health Commission Clinical Research Project (Grant Number 202140203), Shanghai 3-year Action Plan for Public Health under a grant (GWV-10.2-XD13, GWV-10.1-XK15, GWV-10.1-XK18), a strategic collaborative innovation team (SSMU-ZLCX20180601).

CONFLICT OF INTEREST

The authors declare that they do not have any conflicts of interest.

ACKNOWLEDGMENTS

We thank the staff and the participants of the CLHLS study.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.ssph-journal.org/articles/10.3389/ijph.2023.1605934/ full#supplementary-material

Cohort Study. J Clin Endocrinol Metab (2020) 105(1):e597-609. doi:10.1210/ clinem/dgz068

- Tian X, Wang A, Zuo Y, Chen S, Ma Y, Han X, et al. Changes in Serum Uric Acid and the Risk of Cardiovascular Disease and All-Cause Mortality in the General Population. *Nutr Metab Cardiovasc Dis* (2021) 31(5):1401–9. doi:10. 1016/j.numecd.2020.12.034
- Li B, Chen L, Hu X, Tan T, Yang J, Bao W, et al. Association of Serum Uric Acid with All-Cause and Cardiovascular Mortality in Diabetes. *Diabetes Care* (2023) 46(2):425–33. doi:10.2337/dc22-1339
- Konta T, Ichikawa K, Kawasaki R, Fujimoto S, Iseki K, Moriyama T, et al. Association between Serum Uric Acid Levels and Mortality: a Nationwide Community-Based Cohort Study. *Sci Rep* (2020) 10(1):6066. doi:10.1038/ s41598-020-63134-0
- Ungar A, Rivasi G, Di Bari M, Virdis A, Casiglia E, Masi S, et al. The Association of Uric Acid with Mortality Modifies at Old Age: Data from the Uric Acid Right for Heart Health (URRAH) Study. J Hypertens (2022) 40(4):704–11. doi:10.1097/hjh.000000000003068
- Wu CY, Hu HY, Chou YJ, Huang N, Chou YC, Lee MS, et al. High Serum Uric Acid Levels Are Associated with All-Cause and Cardiovascular, but Not Cancer, Mortality in Elderly Adults. J Am Geriatr Soc (2015) 63(9): 1829–36. doi:10.1111/jgs.13607
- Latif W, Karaboyas A, Tong L, Winchester JF, Arrington CJ, Pisoni RL, et al. Uric Acid Levels and All-Cause and Cardiovascular Mortality in the Hemodialysis Population. *Clin J Am Soc Nephrol* : CJASN. (2011) 6(10): 2470–7. doi:10.2215/CJN.00670111
- Fang J, Alderman MH. Serum Uric Acid and Cardiovascular Mortality the NHANES I Epidemiologic Follow-Up Study, 1971-1992. National Health and Nutrition Examination Survey. *Jama* (2000) 283(18):2404–10. doi:10.1001/ jama.283.18.2404
- Zhao G, Huang L, Song M, Song Y. Baseline Serum Uric Acid Level as a Predictor of Cardiovascular Disease Related Mortality and All-Cause Mortality: a Meta-Analysis of Prospective Studies. *Atherosclerosis* (2013) 231(1):61–8. doi:10.1016/j.atherosclerosis.2013.08.023
- Kamei K, Konta T, Ichikawa K, Sato H, Suzuki N, Kabasawa A, et al. Serum Uric Acid Levels and Mortality in the Japanese Population: the Yamagata (Takahata) Study. *Clin Exp Nephrol* (2016) 20(6):904–9. doi:10.1007/s10157-016-1228-1

- Mazidi M, Katsiki N, Mikhailidis DP, Banach M. Associations of Serum Uric Acid with Total and Cause-specific Mortality: Findings from Individuals and Pooling Prospective Studies. *Atherosclerosis* (2020) 296:49–58. doi:10.1016/j. atherosclerosis.2019.07.019
- Kikuchi A, Kawamoto R, Ninomiya D, Kumagi T. Hyperuricemia Is Associated with All-Cause Mortality Among Males and Females: Findings from a Study on Japanese Community-Dwelling Individuals. *Metabol Open* (2022) 14:100186. doi:10.1016/j.metop.2022.100186
- Chen J. Serum Uric Acid Level and All-Cause and Cardiovascular Mortality in Chinese Elderly: A Community-Based Cohort Study in Shanghai. Nutr Metab Cardiovasc Dis (2021) 31(12):3367–76. doi:10.1016/j.numecd.2021.08.042
- Yang Y, Fan Y, Li J, Liu B, Shao Y, Cao H, et al. Serum Uric Acid as a Predictor for Cardiovascular and All-Cause Mortality in Women versus Men. Int J Cardiol (2015) 185:125–8. doi:10.1016/j.ijcard.2015.03.121
- Zeng Y, Feng Q, Hesketh T, Christensen K, Vaupel JW. Survival, Disabilities in Activities of Daily Living, and Physical and Cognitive Functioning Among the Oldest-Old in China: a Cohort Study. *Lancet* (2017) 389(10079):1619–29. doi:10.1016/S0140-6736(17)30548-2
- Sha S, Xu Y, Chen L. Loneliness as a Risk Factor for Frailty Transition Among Older Chinese People. BMC Geriatr (2020) 20(1):300. doi:10.1186/s12877-020-01714-5
- 25. Cang Y, Xu S, Zhang J, Ju J, Chen Z, Wang K, et al. Serum Uric Acid Revealed a U-Shaped Relationship with All-Cause Mortality and Cardiovascular Mortality in High Atherosclerosis Risk Patients: The ASSURE Study. Front Cardiovasc Med (2021) 8:641513. doi:10.3389/fcvm.2021.641513
- Hu SL, Liu CS, Lin CH, Davidson LE, Li CI, Lin CC, et al. Uric Acid and Mortality in Elderly Chinese: a 10-year Population-Based Cohort Study. J Am Geriatr Soc (2012) 60(9):1783–5. doi:10.1111/j.1532-5415.2012.04138.x
- Hu P, Seeman TE, Harris TB, Reuben DB. Is Serum Uric Acid Level Associated with All-Cause Mortality in High-Functioning Older Persons: MacArthur Studies of Successful Aging? J Am Geriatr Soc (2001) 49(12):1679–84. doi:10. 1111/j.1532-5415.2001.49279.x
- Ioannou GN, Boyko EJ. Effects of Menopause and Hormone Replacement Therapy on the Associations of Hyperuricemia with Mortality. *Atherosclerosis* (2013) 226(1):220–7. doi:10.1016/j.atherosclerosis.2012.10.044
- Juraschek SP, Tunstall-Pedoe H, Woodward M. Serum Uric Acid and the Risk of Mortality during 23 Years Follow-Up in the Scottish Heart Health Extended Cohort Study. *Atherosclerosis* (2014) 233(2):623–9. doi:10.1016/j. atherosclerosis.2014.01.026
- 30. D'silva K, Yokose C, Lu L, Zhang Y, Choi H. OP0015 SEX-SPECIFIC U-SHAPED RELATIONSHIP BETWEEN SERUM URATE AND MORTALITY IN THE UNITED STATES GENERAL POPULATION. Ann Rheum Dis (2020) 79(1):10–1. doi:10.1136/annrheumdis-2020-eular.2229
- Cheong E, Ryu S, Lee JY, Lee SH, Sung JW, Cho DS, et al. Association between Serum Uric Acid and Cardiovascular Mortality and All-Cause Mortality: a Cohort Study. J Hypertens (2017) 35(1):S3–S9. doi:10.1097/HJH.000000000001330
- Kuo CF, See LC, Yu KH, Chou JJ, Chiou MJ, Luo SF. Significance of Serum Uric Acid Levels on the Risk of All-Cause and Cardiovascular Mortality. *Rheumatology* (Oxford, England) (2013) 52(1):127–34. doi:10.1093/rheumatology/kes223
- Chang DY, Wang JW, Chen M, Zhang LX, Zhao MH. Association between Serum Uric Acid Level and Mortality in China. *Chin Med J* (2021) 134(17): 2073–80. doi:10.1097/cm9.00000000001631

- 34. Yan D, Tu Y, Jiang F, Wang J, Zhang R, Sun X, et al. Uric Acid Is Independently Associated with Diabetic Kidney Disease: a Cross-Sectional Study in a Chinese Population. *PloS one* (2015) 10(6):e0129797. doi:10.1371/journal.pone.0129797
- 35. Xu K, Zhao X, Fu X, Xu K, Li Z, Miao L, et al. Gender Effect of Hyperuricemia on the Development of Nonalcoholic Fatty Liver Disease (NAFLD): A Clinical Analysis and Mechanistic Study. *Biomed Pharmacother = Biomedecine pharmacotherapie* (2019) 117:109158. doi:10.1016/j.biopha.2019.109158
- 36. Yu XL, Shu L, Shen XM, Zhang XY, Zheng PF. Gender Difference on the Relationship between Hyperuricemia and Nonalcoholic Fatty Liver Disease Among Chinese: An Observational Study. *Medicine* (2017) 96(39):e8164. doi:10.1097/MD.00000000008164
- Wingrove CS, Walton C, Stevenson JC. The Effect of Menopause on Serum Uric Acid Levels in Non-obese Healthy Women. *Metabolism* (1998) 47(4): 435–8. doi:10.1016/s0026-0495(98)90056-7
- Antón FM, García Puig J, Ramos T, González P, Ordás J. Sex Differences in Uric Acid Metabolism in Adults: Evidence for a Lack of Influence of Estradiol-17 Beta (E2) on the Renal Handling of Urate. *Metab Clin Exp* (1986) 35(4): 343–8. doi:10.1016/0026-0495(86)90152-6
- Khosla S, Melton LJ, 3rd, Atkinson EJ, O'Fallon WM. Relationship of Serum Sex Steroid Levels to Longitudinal Changes in Bone Density in Young versus Elderly Men. J Clin Endocrinol Metab (2001) 86(8):3555–61. doi:10.1210/jcem. 86.8.7736
- 40. Hak AE, Choi HK. Menopause, Postmenopausal Hormone Use and Serum Uric Acid Levels in US Women-Tthe Third National Health and Nutrition Examination Survey. *Arthritis Res Ther* (2008) 10(5):R116. doi:10.1186/ ar2519
- 41. Zhang X, Meng Q, Feng J, Liao H, Shi R, Shi D, et al. The Prevalence of Hyperuricemia and its Correlates in Ganzi Tibetan Autonomous Prefecture, Sichuan Province, China. *Lipids Health Dis* (2018) 17(1):235. doi:10.1186/s12944-018-0882-6
- 42. Xu J, Peng H, Ma Q, Zhou X, Xu W, Huang L, et al. Associations of Non-high Density Lipoprotein Cholesterol and Traditional Blood Lipid Profiles with Hyperuricemia Among Middle-Aged and Elderly Chinese People: a Community-Based Cross-Sectional Study. *Lipids Health Dis* (2014) 13:117. doi:10.1186/1476-511X-13-117
- 43. Kuwabara M, Borghi C, Cicero AFG, Hisatome I, Niwa K, Ohno M, et al. Elevated Serum Uric Acid Increases Risks for Developing High LDL Cholesterol and Hypertriglyceridemia: A Five-Year Cohort Study in Japan. *Int J Cardiol* (2018) 261:183–8. doi:10.1016/j.ijcard.2018.03.045
- 44. Tseng WC, Chen YT, Ou SM, Shih CJ, Tarng DCTaiwan Geriatric Kidney Disease U-shaped Association between Serum Uric Acid Levels with Cardiovascular and All-Cause Mortality in the Elderly: The Role of Malnourishment. J Am Heart Assoc (2018) 7(4). doi:10.1161/jaha.117.007523

Copyright © 2023 Dong, Wang, Wang, Chang, Liu, Wang, Chen, Liu, Qian, Cai and Hu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.